2019 Galafold Revenue Nearly Doubled to $182.2M
On Track to Achieve 2020 Revenue Guidance of $250M-$260MFocused on Pompe Phase 3 PROPEL Study, Manufacturing to Support 2021 BLA and MAA, and Accelerating Expanded Access Program for Infantile-Onset PatientsAdvancing Industry-Leading Rare Disease Gene Therapy PortfolioStrong Balance Sheet with $450M+ Cash – Cash Runway Well into 2022Conference Call and Webcast Today at 8:30 a.m. ETCRANBURY, N.J., March 02, 2020 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019. The Company also summarized recent program updates and reiterated its full-year 2020 guidance.Corporate Highlights for Full-Year 2019 and Year-to-Date 2020Galafold^® (migalastat), the first oral treatment option for people living with Fabry and who have an amenable variant, revenue grew from $91.2 million in full-year 2018 to $182.2 million in full-year 2019, exceeding the high end of the full-year 2019 guidance range of $170 million to $180 million. Over the course of 2019, Amicus received key marketing authorizations around the globe, including Argentina, Brazil, Colombia and Taiwan.
Bay Street News